Results 31 to 40 of about 240,433 (353)
CDK4/6 inhibition in cancer: the cell cycle splicing connection
Molecular & Cellular Oncology, 2019 Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma.
Karen E. Sheppard, Shatha AbuHammad
doaj +1 more source
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis [PDF]
Nucleic Acids Research, 2012 A novel resource centre for TP53 mutations and mutants has been developed (http://p53.fr). TP53 gene dysfunction can be found in the majority of human cancer types. The potential use of TP53 mutation as a biomarker for clinical studies or exposome analysis has led to the publication of thousands of reports describing the TP53 gene status in >10,000 ...
Leroy, Bernard +6 more
openaire +3 more sources
Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. [PDF]
, 2020 Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response.
Boichard, Amélie +2 more
core
Human Mutation, 2003 Ovarian cancer represents the fourth most frequent type of cancer among females and is the leading cause of death from gynecological cancer in the western world. This review describes gene alterations in ovarian cancer. Specific emphasis is placed on genetic alterations and the prevalence of TP53 (p53) gene alterations in the distinct biological ...
Monique, Schuijer, Els M J J, Berns
openaire +2 more sources
TP53 and liver carcinogenesis [PDF]
Human Mutation, 2003 Primary hepatocellular carcinoma (HCC) is one of the most common malignancies and has the fourth highest mortality rate worldwide. The major risk factors, including chronic infections with the hepatitis B or C virus, are exposure to dietary aflatoxin B1(AFB1), vinyl chloride, or alcohol consumption.
Frank, Staib +4 more
openaire +2 more sources
OncoImmunology, 2021 Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors.
Hua You +28 more
doaj +1 more source
TP53-Associated Pediatric Malignancies [PDF]
Genes & Cancer, 2011 Although the majority of pediatric malignancies express wild-type p53, it is well established that germline TP53 mutations or functional inactivation of this pathway by other means contribute to childhood cancer. Epidemiology studies have revealed the existence of diverse inherited mutant TP53 alleles that display different levels of tumor suppressor ...
Emilia M, Pinto +3 more
openaire +2 more sources
Gain-of-function oncogenic mutations in TP53 enhance defined factor-mediated cellular reprogramming [PDF]
, 2011 Cancer is a disorder with various genetic and epigenetic alterations. Genetic alterations such as mutations, i.e., substitutions, amplifications, and deletions of nucleotide sequences, are largely irreversible, whereas epigenetic alterations can be ...
Dyah Laksmi Dewi +9 more
core +2 more sources
TP53 Mutations in Human Meningiomas [PDF]
The International Journal of Biological Markers, 2002 Overexpression of p53 has been reported to play a role in the development of neoplasms of the central nervous system. Meningiomas are generally benign intracranial tumors originating from the meninges. Overexpression of the p53 protein in meningiomas and an association with histological type and recurrence has been reported.
F M, Verheijen +5 more
openaire +2 more sources
Genetic alterations in gliosarcoma and giant cell glioblastoma [PDF]
, 2015 The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma.
ANTONELLI, MANILA +13 more
core +1 more source